Clinical-economic impact of mepolizumab in patients with severe hypereosinophilic asthma

• Diego Bagnasco,
• Massimiliano Povero,
• Lorenzo Pradelli,
• Enrico Heffler,
• Marco Caminati,
• Francesco Menzella,
• Giovanni Rolla,
• Manlio Milanese,
• Carlo Lombardi,
• Elisa Testino,
• Gianenrico Senna,
• Giorgio Walter Canonica,
• Giovanni Passalacqua

Affiliations

Diego Bagnasco

Department of Internal Medicine and Medical Specialties (DIMI), University of Genoa, Genoa Italy

Massimiliano Povero

AdRes, Turin Italy

Lorenzo Pradelli

AdRes, Turin Italy

Enrico Heffler

Department of Internal Medicine, Respiratory Disease Clinic, IRCCS Humanitas Clinical and Research Center, Humanitas University, Milan Italy

Marco Caminati

Asthma Center and Allergy Unit, Verona University and General Hospital, Verona Italy

Francesco Menzella

Unità Operativa di Pneumologia, Arcispedale Santa Maria Nuova, Azienda Ospedaliera di Reggio Emilia, Reggio Emilia Italy

Giovanni Rolla

Allergy and Immunology, AO Mauriziano Hospital, University of Turin, Turin Italy

Manlio Milanese

Division of Pneumology, S.Corona Hospital, Pietra Ligure, Pietra Ligure Italy

Carlo Lombardi

Departmental Unit of Allergology & Respiratory Diseases, Fondazione Poliambulanza, Brescia Italy

Elisa Testino

Department of Internal Medicine and Medical Specialties (DIMI), University of Genoa, Genoa Italy

Gianenrico Senna

Asthma Center and Allergy Unit, Verona University and General Hospital, Verona Italy

Giorgio Walter Canonica

Department of Internal Medicine, Respiratory Disease Clinic, IRCCS Humanitas Clinical and Research Center, Humanitas University, Milan Italy

Giovanni Passalacqua

Department of Internal Medicine and Medical Specialties (DIMI), University of Genoa, Genoa Italy